Ruben Niesvizky, MDEnriched profile
Professor of Medicine; Director, Multiple Myeloma Center · Weill Cornell Medicine / NewYork-Presbyterian Hospital
Overview
Updated 14 Jul 2026
Ruben Niesvizky, MD, is Professor of Medicine at Weill Cornell Medicine / NewYork-Presbyterian Hospital. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 15 companies, 2 NIH-funded awards (2004–2008).
- Top research focus: Multiple Myeloma
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 15 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industrytrials, payments and federal funding
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma
Sponsor: Weill Medical College of Cornell University
InvestigatorPhase 1/PHASE2TerminatedNCT01979276 - Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma
Sponsor: Weill Medical College of Cornell University
InvestigatorPhase 2Active, not recruitingNCT01559935 - Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma
Sponsor: Weill Medical College of Cornell University
InvestigatorPhase 2CompletedNCT01159574
Industry payments
Updated 14 Jul 2026
15 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20253 payments$45,500openpaymentsdata.cms.gov ↗
- Janssen Biotech, Inc.Program year202512 payments$16,840openpaymentsdata.cms.gov ↗
- Karyopharm Therapeutics Inc.Program year20253 payments
NIH funding
Updated 14 Jul 2026
2 NIH research awards on record, funded 2004–2008 per NIH RePORTER. The latest:
- EXPLOITING NOVEL THERAPEUTIC TARGETS IN MULTIPLE MYELOMA (K23M)
Weill Medical Coll of Cornell Univ
FY2008$136,080K23CA109260 - EXPLOITING NOVEL THERAPEUTIC TARGETS IN MULTIPLE MYELOMA (K23M)
Weill Medical Coll of Cornell Univ
FY2007$136,080K23CA109260 - VEGF TRAP FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
Weill Medical Coll of Cornell Univ
FY2007$662M01RR000047
Publications
None on file yet. We only list publications we can confidently match to this person. Why? →
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
425 E. 61st Street, 8th Floor, New York, NY 10065
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗
- Board Certified
American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗ - Board Certified
American Board of Internal Medicine - Hematology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗
Editorial & leadership rolesjournal and society appointments
- Active member
International Myeloma Working Group (sets standards of research and practice in myeloma)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗
Awards & honorshonors on the public record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗
Secondary affiliationsappointments beyond the home institution
- Active member
International Myeloma Working Group
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗ - Scientific/Advisory Board Member
Bristol-Myers Squibb
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗ - Scientific/Advisory Board Member
Janssen Pharmaceutical Company
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗
Media & interviewspress, podcasts and appearances
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- Doximity
doximity.com/pub/ruben-niesvizky-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Ruben-Niesvizky
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - LinkedIn
linkedin.com/in/ruben-niesvizky-0418b8b
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by otherswhere others cite or feature them
- Other
onclive.com/authors/ruben-niesvizky-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.